Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.62 |
| ▸ | AHR | P35869 | 3/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29385902 | 0.82 | TAAR1 (0.68) | TAAR1AHRPNMTMAOBSIGMAR1 | |
| SCHEMBL29349576 | 0.81 | PNMT (0.67) | TAAR1PNMTIDO1CSNK2A1SIGMAR1 | |
| SCHEMBL112200 | 0.81 | PNMT (0.67) | TAAR1PNMTIDO1CSNK2A1SIGMAR1 | |
| SCHEMBL11071591 | 0.80 | AHR (0.64) | TAAR1AHRCYP1B1PNMTIDO1 | |
| Ammonia Solution, Strong SCHEMBL9178453 | 0.79 | PNMT (0.64) | TAAR1PNMTIDO1CSNK2A1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3127848 | 0.79 | PNMT (0.64) | TAAR1PNMTIDO1CSNK2A1SIGMAR1 | |
| SCHEMBL27717640 | 0.79 | TAAR1 (0.53) | TAAR1AHRHRH3PNMTMAOB | |
| SCHEMBL8024771 | 0.78 | AHR (0.61) | TAAR1AHRCYP1B1PNMTIDO1 | |
| SCHEMBL12603805 | 0.78 | AHR (0.61) | TAAR1AHRCYP1B1PNMTIDO1 | |
| SCHEMBL2274647 | 0.78 | HRH3 (1.00) | TAAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470859-B2 | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8470859-B2 | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | TAAR1 122/4885AHR 980/4885HRH3 500/4885 |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | TAAR1 4731/4885AHR 2502/4885HRH3 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.